Barry Rosen PhD

Dr. Barry Rosen recently joined AstraZeneca Discovery Sciences in Cambridge as a VP and Senior Principal Scientist. He focusses on the applications of novel stem cell and genome engineering technologies to drug discovery. He previously worked for many years at the Wellcome Trust Sanger Institute in Cambridge, the UK where he most recently led the Genome Engineering Technology team. His core interests have been in developing both mouse and human stem cell-based disease models through the application of novel and evolving genome engineering technologies, most recently CRISPR based systems. For the past ten years, he has been involved in generating large scale targeted mouse ES cell resources which have been central to the International Mouse Knockout Consortium (IKMC) and International Mouse Phenotyping Consortium (IMPC), worldwide collaborative efforts to functionally annotate the mammalian genome by the production of a mouse mutant for every gene.

He has also been involved in studies of the differentiation of human pluripotent stem cells to the brown adipocyte lineage and other human stem cell differentiation projects. Dr. Rosen did his Ph.D. with Dr. Bruce Spiegelman at Harvard Medical School on adipocyte molecular biology where he studied unexpected links between obesity and the immune system and his postdoctoral work with the late Dr. Rosa Beddington in Edinburgh on mouse molecular embryology. He also is a founding instructor of the annual Wellcome Trust Advanced Course in Genome Engineering of Mammalian Stem Cells held at the Sanger.